Loading
Julie Park led the COG trial that made tandem transplant standard for high-risk neuroblastoma.
Julie Park is Chair of the Department of Oncology at St. Jude Children's Research Hospital and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and immunotherapy, she was study chair of COG ANBL0532, the randomised trial of tandem versus single autologous stem cell transplant in high-risk neuroblastoma that made tandem transplant standard, and is a leader in anti-GD2 immunotherapy studies linked to COG ANBL0032 and dinutuximab. Her papers report the tandem transplant trial in JAMA and the revised International Neuroblastoma Response Criteria consensus statement in the Journal of Clinical Oncology. Her work centres on GD2-directed therapy in paediatric neuroblastoma.
Shares COG ANBL0032, GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares COG ANBL0532, Neuroblastoma (paediatric).
Shares COG ANBL0032, Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares St. Jude Children's Research Hospital, Neuroblastoma (paediatric).